+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 41 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the safety and effectiveness of NEU-411 in people aged 40 to 80 years with early Parkinsons Disease PD who have a specific genetic profile that predicts increased activity in the LRRK2 pathway. This Phase 2 study uses a companion diagnostic genetic test to identify participants with LRRK2-driven PD. The trial aims to compare NEU-411, a brain-penetrant drug that inhibits LRRK2 activity, to a placebo. Participants will be randomly assigned to receive either NEU-411 30 mg once daily or a matching placebo for 52 weeks. After this double-blind treatment period, there will be a safety follow-up visit within two weeks. Those who qualify may continue into an open-label extension phase where they will receive NEU-411 for an additional 26 weeks. Throughout the study, participants will have their Parkinsons symptoms and safety monitored using digital biomarker scores and clinical rating scales. Researchers will assess changes from baseline in the Roche digital biomarker score and the Unified Parkinsons Disease Rating Scale over the 52-week treatment period. Safety will be tracked by recording adverse events through the end of the study. Total participation may last up to 78 weeks including the extension and follow-up.

Age: 40Years - 80YearsAll GendersPhase 2
72 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
E

Actively Recruiting

Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.

Age: 40Years - 75YearsAll GendersPhase 2
127 locations
E

Actively Recruiting

Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.

Age: 55Years - 85YearsAll GendersPhase 2
72 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and behavior of LY4006896 when given intravenously to healthy adults and people with Parkinsons disease. This study compares LY4006896 with a placebo to understand how the drug interacts with the body and its effects over time. The study includes both healthy volunteers and participants diagnosed with Parkinsons disease, aiming to collect important safety and pharmacokinetic data. Participants with Parkinsons disease will undergo up to four doses of LY4006896 or placebo during a screening period lasting up to 120 days, followed by treatment and follow-up lasting up to 61 weeks. Healthy participants will receive a single escalating dose or placebo in a screening period lasting up to 35 days and be followed for up to 48 weeks. The study involves random assignment to receive either LY4006896 or placebo, with single blinding to ensure unbiased results. Throughout the study, participants will have regular assessments including monitoring for serious or treatment-emergent adverse events, blood sampling for drug concentration measurement, and evaluations of Parkinsons disease-related markers such as alpha-synuclein in skin and cerebrospinal fluid. Participants will be followed for up to 78 weeks Parkinsons group or 53 weeks healthy group to evaluate safety and drug effects. The trial includes detailed cognitive assessments and eligibility screening to ensure participant safety and data reliability.

Age: 30Years - 85YearsAll GendersPhase 1
14 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of two different doses of the drug AP-472 as an add-on treatment to levodopa in people with Parkinsons disease who experience motor fluctuations. This Phase 2 study aims to compare these doses with a placebo over a 14-week period to better understand how AP-472 affects motor symptoms when combined with standard levodopa therapy. Participants will be randomly assigned to receive either 100 mg or 300 mg of AP-472 daily, or a placebo, without knowing which treatment they are receiving. The study includes a screening phase, a 4-week period with stable Parkinsons medications, and a 12-week treatment phase during which some adjustments to levodopa dosing are allowed if necessary. During their participation, individuals will be closely monitored with assessments including motor diaries to track daily OFF time, various Parkinsons disease rating scales, and sleepiness questionnaires. The primary focus is on changes in average daily OFF time after 12 weeks of treatment. Safety and effectiveness will be evaluated throughout, with the entire study lasting about 14 weeks from start to finish.

Age: 30Years - 80YearsAll GendersPhase 2
30 locations
E

Actively Recruiting

Researchers are evaluating the drug VIM0423 in adults with Parkinsons disease who experience tremors that do not respond well to dopaminergic therapy. The study aims to determine if VIM0423 improves tremor symptoms, is well tolerated, and enhances daily function and quality of life. This Phase 2, multicenter, randomized, placebo-controlled trial will enroll up to 80 participants with Parkinsons tremor, a symptom that affects many and is often the most troubling for patients. Participants are divided into two groups Cohort 1 includes those on stable dopaminergic therapy with residual tremor, and Cohort 2 includes those who have never used dopaminergic therapies. Both cohorts are randomized to receive either VIM0423 or matching placebo, with doses up to five pills once daily for seven weeks. The study is triple-blinded, meaning neither participants nor investigators know the assigned treatment. The total participation lasts up to 12 weeks, including screening, treatment with tapering, and safety follow-up. During the study, participants attend six in-person visits for assessments including clinical evaluations, lab tests, and EKGs. They will wear a device to monitor tremor and complete self-assessments of tremor impact on daily activities. The primary outcome is change in Parkinsons disease symptoms measured by the Movement Disorder Society Unified Parkinsons Disease Rating Scale from baseline to Week 6. Secondary measures include clinician and patient global impressions, tremor-related daily living scales, and sleep assessments. Safety and adverse events are closely monitored throughout.

Age: 18Years - 65YearsAll GendersPhase 2
30 locations

1-10 of 41

1